Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol Myers Squibb new CEO buys company shares

…

Bristol Myers Squibb CEO Chris Boerner Buys Up Stock

…

Fortunes Can Be Made With Bristol-Myers Squibb

Taking a closer look at one of the largest companies in the pharmaceutical industry…

[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

Avidity Biosciences leaps on Bristol-Myers research tie-up

Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co...…

Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are Better

…

: Avidity’s stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

Avidity Biosciences Inc. RNA said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal…

Global Non-Hodgkin Lymphoma Therapeutics Market Size To Worth USD 16.64 Billion by 2032 | CAGR of 7.8%

The Global Non-Hodgkin Lymphoma Therapeutics Market Size was valued at USD 7.85 Billion in 2022. The Worldwide Non-Hodgkin Lymphoma Therapeutics…

Bristol-Myers Squibb: The Patent Expiry Challenge

…

Bristol Myers Squibb: A Bitter Pill But Still A Buy

…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

Bristol-Myers Squibb: A Tough But Cheap Spot

…

Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback

Bristol Myers Squibb (BMY) and 2seventy bio, Inc.s efforts to seek approval for the label expansion of Abecma for earlier…

Dow Jones, S&P 500, Nasdaq: US-Anleger kaufen weiter ein

Bei den Einzelwerten geben die Aktien von Bristol Myers Squibb zum Handelsstart um rund vier Prozent nach. Dabei spielt auch…

Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application By Investing.com

Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application…

Bristol-Meyers Squibb shares fall as FDA delays blood cancer therapy decision

Bristol-Myers Squibb Co (NYSE:BMY) shares fell almost 5% after the company announced that a Food and Drug Administration (FDA) decision…

Bristol-Myers Squibb: Bayer-Nachrichten sind ein schlechtes Omen - Aktienanalyse

London (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von Barclays: Die Analysten von Barclays stufen die Aktie von Bristol-Myers Squibb Company (ISIN: US1101221083, WKN:…

Stocks making the biggest premarket moves: Boeing, Bristol-Myers Squibb, Chegg, Krispy Kreme and more

These are the stocks posting the largest moves in the premarket.…

: Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment

Shares of Bristol Myers Squibb, 2seventy bio fell early Monday as FDA said it would miss a regulatory action date…

Biggest stock movers today: Bristol Myers Squibb, NuScale Power, Chegg and more

…

Bayer Stock Plunges, Bristol Myers Squibb Falls After Negative Drug-Trial Result

The week is off to an ugly start for some pharmaceutical investors. Bayer said it is halting a trial for asundexian,…

Bristol Myers Squibb: Bright Future Ahead

…

Bristol Myers Squibb shares dip as market shows mixed results By Investing.com

Bristol Myers Squibb shares dip as market shows mixed results…

Bristol-Myers Squibb Company (BMY) Management Presents at Jefferies London Healthcare Conference (Transcript)

…

Bristol-Myers Squibb slashed, Energizer hit with 3 downgrades: 4 big analyst cuts By Investing.com

Bristol-Myers Squibb slashed, Energizer hit with 3 downgrades: 4 big analyst cuts…

Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis

The hypertrophic cardiomyopathy market dynamics are anticipated to change during the forecast period (2023–2032) due to the expected launch of…

Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment

The stock isnt nearly as risky as its low valuation suggests.…

Bristol-Myers Squibb Company (BMY) Management Presents at 2023 UBS BioPharma Conference (Transcript)

…

Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?

Theres a lot more at stake than bragging rights.…

Bristol Myers Squibb raises $4.5B through senior unsecured notes offering

…

Merck strengthens growth narrative, Bristol-Myers Squibb difficult to own - BMO Capital By Investing.com

Merck strengthens growth narrative, Bristol-Myers Squibb difficult to own - BMO Capital…

Bristol Myers Squibb (BMY) Q3 2023 Earnings Call Transcript

BMY earnings call for the period ending September 30, 2023.…

Stocks making the biggest moves midday: Merck, Bristol-Myers Squibb, Align Technology and more

These are the stocks posting the largest moves in midday trading.…

Bristol-Myers Squibb (BMY) Q3 2023 Earnings Call Transcript

…

SCLX: An Innovative and Growing Pain Management Company

By Brad Sorensen, CFA NASDAQ:SCLX READ THE FULL SCLX RESEARCH REPORT Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on…

Bristol Myers Squibb shares drop 4% premarket after it resets expectations

Shares of Bristol-Myers Squibb Co (NYSE:BMY) dropped 4% in pre-market trading, erasing nearly $5 billion from the pharmaceutical companys market value....…

Bristol-Myers Squibb Company 2023 Q3 - Results - Earnings Call Presentation

…

Bristol-Myers Squibb falls despite raised full-year profit guidance By Investing.com

Bristol-Myers Squibb falls despite raised full-year profit guidance…

: Bristol-Myers Squibb earnings top estimates

Bristol-Myers Squibb Co. BMY on Thursday posted net income of $1.928 billion, or 93 cents a share, for the third…

Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition

Bristol Myers Squibb’s revenue was in line with estimates, but fell slightly from the same period last year due to…

Why LianBio Stock Is Skyrocketing Today

Investors are loving LianBios new deal with Bristol Myers Squibb.…

Bristol-Myers Squibb: Time To Get Greedy

…

MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb

MONSEY, N.Y., Oct. 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating…

Is Bristol Myers Squibb Stock a Buy Now?

Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio.…

Is Bristol Myers Squibb Stock a Buy Now? @themotleyfool #stocks $BMY

Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio.…

Institutional Investors Dominate Bristol-Myers Squibb’s Shareholding Structure By Investing.com

Institutional Investors Dominate Bristol-Myers Squibb’s Shareholding Structure…

BUSINESS WIRE: Cellares gibt erweiterte Vereinbarung mit Bristol Myers Squibb bekannt, die ein zweites CAR-T Programm in das Technologieübernahme-Partnerschaftsprogramm von Cellares einbezieht

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Im Rahmen dieser erweiterten Vereinbarung stellt Cellares…

BUSINESS WIRE: Cellares: estensione dellaccordo con Bristol Myers Squibb per includere un secondo programma CAR-T di partnership per ladozione della tecnologia Cellares

Questo report è stato trasmesso da Businesswire. Solo lazienda emittente è resposabile del suo contenuto.In base a tale accordo ampliato,…

The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer

Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.…